

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1-61. (Cancelled)

62. (Currently Amended) An immunogenic polypeptide comprising a human IgE CH3 domain located between two non-placental mammalian IgE domains, wherein said immunogenic polypeptide is effective to induce an anti-human IgE response in a human The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH2 domain, and the other of said two non-placental mammalian IgE domains is an opossum IgE CH4 domain.

63. (Currently Amended) An immunogenic polypeptide comprising a human IgE CH3 domain located between two non-placental mammalian IgE domains, wherein said immunogenic polypeptide is effective to induce an anti-human IgE response in a human The immunogenic polypeptide of claim 55, wherein the sequence of said immunogenic polypeptide is as set forth in SEQ ID NO:8.

64-82. (Cancelled)

83. (Previously Presented) An immunogenic polypeptide consisting of a human IgE CH3 domain, an opossum IgE CH2 domain, and an opossum IgE CH4 domain, wherein said human IgE CH3 domain is located between said opossum IgE CH2 domain and said opossum IgE CH4 domain.